<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413255</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-020-1001</org_study_id>
    <secondary_id>U1111-1163-9637</secondary_id>
    <nct_id>NCT02413255</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      ascending single- and multiple-doses of TAK-020 in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-020. TAK-020 is being tested to evaluate
      safety and tolerability of single doses and 7 days multiple doses of TAK-020 in healthy
      volunteers. This study will look at the PK characteristics (how the drug acts throughout the
      body) of the drug and safety and tolerability (lab results, vital signs, ECG, and side
      effects) in healthy participants who take TAK-020.

      The study will enroll a total of approximately 120 participants. This study is designed to
      consist of 2 sequential parts: Part 1-a SRD, and Part 2-a MRD. Healthy participants for Part
      1 will be enrolled into 9 cohorts. Each cohort will have 8 randomized participants with
      receiving a single dose of TAK-020, and 2 receiving matching placebo under fasted conditions.
      In Cohorts 1-9 doses of 0.1, 0.5, 2.5, 4.4, 8.8, 17.5, 35, 70 and 105 mg will be evaluated.

      Healthy participants for Part 2 will be enrolled into 7 cohorts. Each cohort will have 8
      randomized participants, with participants receiving one dose of TAK-020 on Day 1, followed
      by a washout on Day 2, then daily dosing on Days 3-9 of TAK-020 with 2 participants receiving
      matching placebo under fasted conditions. In Cohorts 1-4 doses of 3.75, 5.75, 13 and 25 mg
      will be evaluated. For Cohorts 5-7, the subsequent dose level is to be determined based on
      data from Part 1 and review of safety, tolerability and PK data from Part 2 Cohorts 1-4.

      This single-center trial will be conducted in the United States. The overall time to
      participate in this study is up to 45 days. Participants in Part 1 will make multiple visits
      to the clinic including a period of confinement to the clinic and will be contacted by
      telephone 14 days after the last dose of study drug for a follow-up assessment. Participants
      in Part 2 will make multiple visits to the clinic including a period of confinement to the
      clinic and will be observed at the clinic 17 days after the last dose of study drug for a
      follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2015</start_date>
  <completion_date type="Actual">May 4, 2017</completion_date>
  <primary_completion_date type="Actual">May 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD)</measure>
    <time_frame>First dose of study drug up to and including 30 days after last dose of study drug (Up to 31 days) for Part 1</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurred or worsened after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Values (MAV) for Safety Laboratory Findings at Least Once Post-dose in Part 1 (SRD)</measure>
    <time_frame>From Day 1 to Day 14 of Part 1</time_frame>
    <description>Safety laboratory tests includes hematology, serum chemistries, and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 1 (SRD)</measure>
    <time_frame>From Day 1 to Day 14 of Part 1</time_frame>
    <description>Vital signs include oral temperature, respiratory rate, sitting blood pressure (after 5 minutes resting) and pulse beats per minute (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With MAV for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose in Part 1 (SRD)</measure>
    <time_frame>From Day 1 to Day 14 in Part 1</time_frame>
    <description>A standard 12-lead ECG was performed. Change from baseline=CFB.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 2 Multiple-rising Dose (MRD)</measure>
    <time_frame>First dose of study drug up to and including 30 days after last dose of study drug (Up to 39 days) in Part 2</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurred or worsened after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With MAV for Safety Laboratory Findings at Least Once Post-dose in Part 2 (MRD)</measure>
    <time_frame>From Day 1 to Day 17 in Part 2</time_frame>
    <description>Safety laboratory tests include hematology, and serum chemistries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 2 (MRD)</measure>
    <time_frame>From Day 1 to Day 17 in Part 2</time_frame>
    <description>Vital signs include oral temperature respiratory rate, sitting blood pressure (after 5 minutes resting) and pulse (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With MAV for Safety ECG Parameters at Least Once Post-dose in Part 2 (MRD)</measure>
    <time_frame>From Day 1 to Day 17 in Part 2</time_frame>
    <description>A standard 12-lead ECG was performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple time-points (up to 24 hours) post dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 Hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞:Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac(AUC): Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 After a Single Dose for TAK-020 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac(Cmax): Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax After a Single Dose for TAK-020 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Disposition Phase Half-life for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2z : Terminal Disposition Phase Half-life (T1/2z) for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lambda z (Λz): Terminal Disposition Phase Rate Constant for TAK-020 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lamda z (Λz):Terminal Disposition Phase Rate Constant for TAK-020 (MRD)</measure>
    <time_frame>From pre-dose to 96 hours post-dose in Part 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
    <description>CL/F was calculated as dose/AUC∞.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
    <description>CL/F was calculated as dose/AUCτ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
    <description>Vz/F was calculated as (CL/F)/λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
    <description>Vz/F was calculated as (CL/F)/λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae(0-24) : Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
    <description>Ae(0-24) was calculated as calculated as Cur*Vur, where Cur was the concentration of drug excreted in urine and Vur is the volume of urine excreted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae(0-24): Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 1 and Day 9 in Part 2</time_frame>
    <description>Ae(0-24) is calculated as calculated as Cur*Vur, where Cu was the concentration of drug excreted in urine and Vur is the volume of urine excreted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae(0-96): Amount of Drug Excreted in Urine From Time 0 to Time 96 Hours for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
    <description>Fe was calculated as (Aet/dose)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 1 and Day 9 in Part 2</time_frame>
    <description>Fe was calculated as (Aet/dose)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fe(0-96): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
    <description>Fe was calculated as (Aet/dose)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) for TAK-020 in Part 1 (SRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
    <description>CLr was calculated as (Ae96/AUCt)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
    <description>CLr was calculated as (Ae24/AUC24)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R: Linearity Index Calculated as AUC24 at Steady State/AUC∞ After a Single Dose for TAK-020 in Part 2 (MRD)</measure>
    <time_frame>Pre-dose and multiple timepoints (Up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1-9: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1: TAK-020 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 0.1 mg, solution, orally once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2: TAK-020 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3: TAK-020 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 4: TAK-020 4.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 5: TAK-020 8.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 6: TAK-020 17.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 7: TAK-020 35 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 8: TAK-020 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 9: TAK-020 105 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 1-6: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 1: TAK-020 3.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 2: TAK-020 5.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 3: TAK-020 13 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 4: TAK-020 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 5: TAK-020 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 6: TAK-020 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020</intervention_name>
    <description>TAK-020 oral solution</description>
    <arm_group_label>Part 1 Cohort 1: TAK-020 0.1 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 2: TAK-020 0.5 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 3: TAK-020 2.5 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 4: TAK-020 4.4 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 5: TAK-020 8.8 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 6: TAK-020 17.5 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 7: TAK-020 35 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 8: TAK-020 70 mg</arm_group_label>
    <arm_group_label>Part 1 Cohort 9: TAK-020 105 mg</arm_group_label>
    <arm_group_label>Part 2 Cohort 1: TAK-020 3.75 mg</arm_group_label>
    <arm_group_label>Part 2 Cohort 2: TAK-020 5.75 mg</arm_group_label>
    <arm_group_label>Part 2 Cohort 3: TAK-020 13 mg</arm_group_label>
    <arm_group_label>Part 2 Cohort 4: TAK-020 25 mg</arm_group_label>
    <arm_group_label>Part 2 Cohort 5: TAK-020 45 mg</arm_group_label>
    <arm_group_label>Part 2 Cohort 6: TAK-020 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-020 Placebo</intervention_name>
    <description>TAK-020 placebo-matching oral solution</description>
    <arm_group_label>Part 1 Cohort 1-9: Placebo</arm_group_label>
    <arm_group_label>Part 2 Cohort 1-6: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Participant eligibility is determined according to the following criteria prior to entry
        into the study:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. Participant or, when applicable, the participant's legally acceptable representative
             signs and dates a written, informed consent form and any required privacy
             authorization prior to the initiation of any study procedures including requesting
             that a participant fast for any laboratory evaluations.

          3. Participant is a healthy adult male or female.

          4. The participant is a health adult male or female aged 18 to 55 years, inclusive, at
             the time of informed consent and first study medication dose.

          5. The participant weighs at least 45 kilogram (kg) and has a body mass index (BMI)
             between 18.0 and 32.0 kilogram per square meter (kg/m^2), inclusive at Screening and
             Day -1.

          6. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          7. A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use adequate contraception from signing of
             informed consent throughout the duration of the study and until the next menstrual
             period or 30 days after last dose, whichever is first. If the next menstrual period is
             delayed, a pregnancy test will be required for exclusion of pregnancy.

        Exclusion Criteria

        Any participant who meets any of the following criteria will not qualify for entry into the
        study:

          1. The participant has received any investigational compound within 30 days prior to
             Screening.

          2. The participant is an immediate family member, study site employee, or in a dependent
             relationship with a study site employee who is involved in the conduct of this study
             (example, spouse, parent, child, sibling) or may consent under duress.

          3. Participant has a known hypersensitivity to any component of the formulation of
             TAK-020, Captisol or related compounds.

          4. The participant has a positive urine drug result for drugs of abuse at Screening or
             Check-in (Day -1).

          5. The participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol abuse (defined as 4 or more alcoholic beverages per day) within 1
             year prior to the Screening visit or is unwilling to agree to abstain from alcohol and
             drugs throughout the study. One unit is equivalent to a half-pint of beer or 1 measure
             of spirits or 1 glass of wine.

          6. Participant has taken any excluded medication, supplements, or food products,
             Prohibited Medications and Dietary Products.

          7. If female, the participant is pregnant or lactating or intending to become pregnant
             before, during or within 1 month after exit from this study (30 days post last dose);
             or intending to donate ova during such time period.

          8. If male, the participant intends to donate sperm during the course of this study or
             for 12 weeks thereafter.

          9. Participant has evidence of current cardiovascular, central nervous system, hepatic,
             hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious
             allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any
             finding in the participant's medical history, physical examination, or safety
             laboratory tests giving reasonable suspicion of a disease that would contraindicate
             taking TAK-020, or a similar drug in the same class, or that might interfere with the
             conduct of the study. This includes, but is not limited to, peptic ulcer disease,
             seizure disorders, and cardiac arrhythmias.

         10. Participant has current or recent (within 6 months) gastrointestinal disease that
             would be expected to influence the absorption of drugs (that is, a history of
             malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent
             [more than once per week] occurrence of heartburn, or any surgical intervention
             [example, cholecystectomy]).

         11. Participant has a history of cancer, except basal cell carcinoma which has been in
             remission for at least 5 years prior to Day 1.

         12. Participant has used nicotine-containing products (including but not limited to
             cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28
             days prior to Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day
             -1).

         13. The participant has poor peripheral venous access.

         14. Participant has donated or lost 450 milliliter (mL) or more of his or her blood volume
             (including plasmapheresis), or had a transfusion of any blood product within 30 days
             prior to Day 1.

         15. Vaccination with any live vaccine within 4 weeks of study drug administration.

         16. Participant has a Screening or Check-in (Day -1) abnormal (clinically significant)
             ECG. Entry of any participant with an abnormal (not clinically significant) ECG must
             be approved, and documented by signature by the principal investigator medically
             qualified sub investigator.

         17. Participant has QT interval with Fridericia correction method (QTcF) greater than (&gt;)
             450 millisecond (msec) for men and women or PR outside the range of 120 to 220 msec
             confirmed upon repeat testing within a maximum of 30 minutes, at the Screening Visit
             or Check-in (Day -1).

         18. Participant has abnormal Screening or Day -1 laboratory values that suggest a
             clinically significant underlying disease or participant with the following lab
             abnormalities:

               1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.2* the
                  upper limit of normal (ULN).

               2. Positive screen test for drugs of abuse.

               3. Positive blood screen for hepatitis B surface antigen (HBsAg), hepatitis C virus
                  (HCV), or human immunodeficiency virus-1 or -2 antibodies.

               4. A positive test for tuberculosis (TB) (QuantiFERON).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>June 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02413255/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02413255/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative sites in the United States from 18 March 2015 to 04 May 2017.</recruitment_details>
      <pre_assignment_details>Healthy volunteers were enrolled to receive TAK-020 oral solution Single Rising Doses (SRD) [0.1, 0.5, 2.5, 4.4, 8.8, 17.5, 35, 70, 105 milligrams (mgs)] or placebo in Part 1 or Multiple Rising Doses (MRD) [3.75, 5.75, 13, 25, 45, 60 mgs] or Placebo in Part 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Cohort 1-9: Placebo</title>
          <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
          <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
          <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
          <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
          <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
          <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
          <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
        </group>
        <group group_id="P8">
          <title>Part 1 Cohort 7: TAK-020 35 mg</title>
          <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
        </group>
        <group group_id="P9">
          <title>Part 1 Cohort 8: TAK-020 70 mg</title>
          <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
        </group>
        <group group_id="P10">
          <title>Part 1 Cohort 9: TAK-020 105 mg</title>
          <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
        </group>
        <group group_id="P11">
          <title>Part 2 Cohort 1-6: Placebo</title>
          <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
        </group>
        <group group_id="P12">
          <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
          <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
        </group>
        <group group_id="P13">
          <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
          <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
        </group>
        <group group_id="P14">
          <title>Part 2 Cohort 3: TAK-020 13 mg</title>
          <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
        </group>
        <group group_id="P15">
          <title>Part 2 Cohort 4: TAK-020 25 mg</title>
          <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
        </group>
        <group group_id="P16">
          <title>Part 2 Cohort 5: TAK-020 45 mg</title>
          <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
        </group>
        <group group_id="P17">
          <title>Part 2 Cohort 6: TAK-020 60 mg</title>
          <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1 Cohort 1-9: Placebo</title>
          <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
          <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
          <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
          <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
          <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
          <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
          <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
        </group>
        <group group_id="B8">
          <title>Part 1 Cohort 7: TAK-020 35 mg</title>
          <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
        </group>
        <group group_id="B9">
          <title>Part 1 Cohort 8: TAK-020 70 mg</title>
          <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
        </group>
        <group group_id="B10">
          <title>Part 1 Cohort 9: TAK-020 105 mg</title>
          <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
        </group>
        <group group_id="B11">
          <title>Part 2 Cohort 1-6: Placebo</title>
          <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
        </group>
        <group group_id="B12">
          <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
          <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
        </group>
        <group group_id="B13">
          <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
          <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
        </group>
        <group group_id="B14">
          <title>Part 2 Cohort 3: TAK-020 13 mg</title>
          <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
        </group>
        <group group_id="B15">
          <title>Part 2 Cohort 4: TAK-020 25 mg</title>
          <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
        </group>
        <group group_id="B16">
          <title>Part 2 Cohort 5: TAK-020 45 mg</title>
          <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
        </group>
        <group group_id="B17">
          <title>Part 2 Cohort 6: TAK-020 60 mg</title>
          <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="12"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="6"/>
            <count group_id="B15" value="6"/>
            <count group_id="B16" value="6"/>
            <count group_id="B17" value="6"/>
            <count group_id="B18" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="10.93"/>
                    <measurement group_id="B2" value="46.0" spread="10.06"/>
                    <measurement group_id="B3" value="38.0" spread="11.15"/>
                    <measurement group_id="B4" value="38.0" spread="11.82"/>
                    <measurement group_id="B5" value="29.0" spread="11.82"/>
                    <measurement group_id="B6" value="35.8" spread="11.44"/>
                    <measurement group_id="B7" value="38.2" spread="12.56"/>
                    <measurement group_id="B8" value="33.7" spread="8.24"/>
                    <measurement group_id="B9" value="34.3" spread="12.61"/>
                    <measurement group_id="B10" value="34.8" spread="7.81"/>
                    <measurement group_id="B11" value="37.0" spread="8.83"/>
                    <measurement group_id="B12" value="34.2" spread="8.59"/>
                    <measurement group_id="B13" value="43.2" spread="9.02"/>
                    <measurement group_id="B14" value="29.3" spread="9.40"/>
                    <measurement group_id="B15" value="35.7" spread="9.40"/>
                    <measurement group_id="B16" value="36.2" spread="11.96"/>
                    <measurement group_id="B17" value="34.8" spread="10.01"/>
                    <measurement group_id="B18" value="36.0" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic and Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="10"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>Body Mass Index = weight (kg)/[height (m)^2]</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.18" spread="3.741"/>
                    <measurement group_id="B2" value="27.04" spread="3.823"/>
                    <measurement group_id="B3" value="27.24" spread="3.308"/>
                    <measurement group_id="B4" value="25.77" spread="4.359"/>
                    <measurement group_id="B5" value="23.91" spread="3.221"/>
                    <measurement group_id="B6" value="23.23" spread="2.549"/>
                    <measurement group_id="B7" value="25.87" spread="3.332"/>
                    <measurement group_id="B8" value="23.98" spread="1.408"/>
                    <measurement group_id="B9" value="24.47" spread="2.263"/>
                    <measurement group_id="B10" value="26.89" spread="1.468"/>
                    <measurement group_id="B11" value="25.36" spread="2.645"/>
                    <measurement group_id="B12" value="27.26" spread="3.516"/>
                    <measurement group_id="B13" value="24.97" spread="4.563"/>
                    <measurement group_id="B14" value="25.83" spread="2.707"/>
                    <measurement group_id="B15" value="28.64" spread="2.935"/>
                    <measurement group_id="B16" value="25.07" spread="2.124"/>
                    <measurement group_id="B17" value="27.05" spread="2.851"/>
                    <measurement group_id="B18" value="25.82" spread="3.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="11"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never drank</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current drinker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex- drinker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Participant Consumed</title>
          <description>Number of participants who consume alcohol &lt;4 drinks/day is reported.</description>
          <population>Assessment was performed on participants who were current drinkers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="3"/>
                    <count group_id="B8" value="3"/>
                    <count group_id="B9" value="2"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="2"/>
                    <count group_id="B12" value="2"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="1"/>
                    <count group_id="B17" value="0"/>
                    <count group_id="B18" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Xanthine Consumption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Reproductive Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Postmenopausal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically Sterile</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female of Childbearing Potential</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable (Participant was Male)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="6"/>
                    <count group_id="B11" value="12"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="6"/>
                    <count group_id="B15" value="6"/>
                    <count group_id="B16" value="6"/>
                    <count group_id="B17" value="6"/>
                    <count group_id="B18" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurred or worsened after receiving study drug.</description>
        <time_frame>First dose of study drug up to and including 30 days after last dose of study drug (Up to 31 days) for Part 1</time_frame>
        <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-9: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurred or worsened after receiving study drug.</description>
          <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Values (MAV) for Safety Laboratory Findings at Least Once Post-dose in Part 1 (SRD)</title>
        <description>Safety laboratory tests includes hematology, serum chemistries, and urinalysis.</description>
        <time_frame>From Day 1 to Day 14 of Part 1</time_frame>
        <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-9: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Values (MAV) for Safety Laboratory Findings at Least Once Post-dose in Part 1 (SRD)</title>
          <description>Safety laboratory tests includes hematology, serum chemistries, and urinalysis.</description>
          <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium &lt;130 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium &gt;150 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total &gt;34.2 umol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides &gt;2.5*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (BUN) &gt;10.7 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 1 (SRD)</title>
        <description>Vital signs include oral temperature, respiratory rate, sitting blood pressure (after 5 minutes resting) and pulse beats per minute (bpm).</description>
        <time_frame>From Day 1 to Day 14 of Part 1</time_frame>
        <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-9: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 1 (SRD)</title>
          <description>Vital signs include oral temperature, respiratory rate, sitting blood pressure (after 5 minutes resting) and pulse beats per minute (bpm).</description>
          <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="50"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure &lt;85 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure &gt;180 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure &gt;110 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature &lt;35.6 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature &gt;37.7 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With MAV for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose in Part 1 (SRD)</title>
        <description>A standard 12-lead ECG was performed. Change from baseline=CFB.</description>
        <time_frame>From Day 1 to Day 14 in Part 1</time_frame>
        <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1-9: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O10">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MAV for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose in Part 1 (SRD)</title>
          <description>A standard 12-lead ECG was performed. Change from baseline=CFB.</description>
          <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate (beats/min) &lt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="50.0"/>
                    <measurement group_id="O10" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate (beats/min) &gt;120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec[ms]) &lt;=80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (ms) &gt;= 200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (ms) &lt;=300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (ms) &gt;=460</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval (ms) &lt;=300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval (ms) ≥500/ ≥30 CFB and ≥450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval (ms) &lt;= 300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval (ms) ≥500/≥30 CFB and &gt;= 450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (ms) &lt;= 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="83.3"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="83.3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="16.7"/>
                    <measurement group_id="O10" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (ms) &gt;= 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 2 Multiple-rising Dose (MRD)</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurred or worsened after receiving study drug.</description>
        <time_frame>First dose of study drug up to and including 30 days after last dose of study drug (Up to 39 days) in Part 2</time_frame>
        <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1-6: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 2 Multiple-rising Dose (MRD)</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurred or worsened after receiving study drug.</description>
          <population>Safety Analysis Set was comprised of all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With MAV for Safety Laboratory Findings at Least Once Post-dose in Part 2 (MRD)</title>
        <description>Safety laboratory tests include hematology, and serum chemistries.</description>
        <time_frame>From Day 1 to Day 17 in Part 2</time_frame>
        <population>Safety Analysis Set included all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1-6: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MAV for Safety Laboratory Findings at Least Once Post-dose in Part 2 (MRD)</title>
          <description>Safety laboratory tests include hematology, and serum chemistries.</description>
          <population>Safety Analysis Set included all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase &gt;5*ULN (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase &gt;3*ULN (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 2 (MRD)</title>
        <description>Vital signs include oral temperature respiratory rate, sitting blood pressure (after 5 minutes resting) and pulse (bpm).</description>
        <time_frame>From Day 1 to Day 17 in Part 2</time_frame>
        <population>Safety Analysis Set included all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1-6: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 2 (MRD)</title>
          <description>Vital signs include oral temperature respiratory rate, sitting blood pressure (after 5 minutes resting) and pulse (bpm).</description>
          <population>Safety Analysis Set included all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure &lt;85 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure &gt;180 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure &gt;110 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature &lt;35.6 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature &gt;37.7 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With MAV for Safety ECG Parameters at Least Once Post-dose in Part 2 (MRD)</title>
        <description>A standard 12-lead ECG was performed.</description>
        <time_frame>From Day 1 to Day 17 in Part 2</time_frame>
        <population>Safety Analysis Set included all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1-6: Placebo</title>
            <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MAV for Safety ECG Parameters at Least Once Post-dose in Part 2 (MRD)</title>
          <description>A standard 12-lead ECG was performed.</description>
          <population>Safety Analysis Set included all participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate (beats/min) &lt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate (beats/min) &gt;120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) &lt;=80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) &gt;=200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (msec) &lt;=300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (msec) &gt;=460</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval (msec) &lt;=300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval (ms) ≥500/≥ 30 CFB and ≥450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval (msec) &lt;=300</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval (ms) ≥500/≥30 CFB and &gt;= 450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) &lt;=80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) &gt;=180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4631" spread="36.3"/>
                    <measurement group_id="O2" value="1.5529" spread="25.2"/>
                    <measurement group_id="O3" value="13.5475" spread="40.7"/>
                    <measurement group_id="O4" value="24.2013" spread="29.5"/>
                    <measurement group_id="O5" value="42.8329" spread="43.3"/>
                    <measurement group_id="O6" value="105.7708" spread="33.3"/>
                    <measurement group_id="O7" value="155.6549" spread="31.8"/>
                    <measurement group_id="O8" value="446.1922" spread="50.9"/>
                    <measurement group_id="O9" value="345.4612" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.465</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0195</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9752</ci_lower_limit>
            <ci_upper_limit>1.0637</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4167" spread="46.7"/>
                    <measurement group_id="O2" value="40.3204" spread="14.4"/>
                    <measurement group_id="O3" value="64.7590" spread="73.3"/>
                    <measurement group_id="O4" value="161.9015" spread="47.1"/>
                    <measurement group_id="O5" value="300.8684" spread="33.3"/>
                    <measurement group_id="O6" value="423.8189" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6976" spread="34.2"/>
                    <measurement group_id="O2" value="39.6336" spread="17.7"/>
                    <measurement group_id="O3" value="63.6636" spread="34.5"/>
                    <measurement group_id="O4" value="160.6945" spread="33.0"/>
                    <measurement group_id="O5" value="279.6237" spread="34.1"/>
                    <measurement group_id="O6" value="433.4214" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.126</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.1124</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9913</ci_lower_limit>
            <ci_upper_limit>1.2336</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.114</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0900</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9962</ci_lower_limit>
            <ci_upper_limit>1.1838</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="0.50" upper_limit="0.77"/>
                    <measurement group_id="O2" value="0.700" lower_limit="0.48" upper_limit="2.02"/>
                    <measurement group_id="O3" value="0.745" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.825" lower_limit="0.48" upper_limit="1.97"/>
                    <measurement group_id="O5" value="0.780" lower_limit="0.67" upper_limit="1.05"/>
                    <measurement group_id="O6" value="1.010" lower_limit="0.58" upper_limit="2.00"/>
                    <measurement group_id="O7" value="0.630" lower_limit="0.50" upper_limit="1.02"/>
                    <measurement group_id="O8" value="0.725" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O9" value="0.750" lower_limit="0.50" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5402</p_value>
            <method>ANOVA</method>
            <method_desc>Statistical analysis results were obtained using Analysis of Variance (ANOVA) with dose level as a fixed effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple time-points (up to 24 hours) post dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="0.50" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.750" lower_limit="0.52" upper_limit="1.08"/>
                    <measurement group_id="O3" value="0.750" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.750" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O5" value="0.500" lower_limit="0.50" upper_limit="1.02"/>
                    <measurement group_id="O6" value="0.640" lower_limit="0.50" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="0.50" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.750" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.750" lower_limit="0.50" upper_limit="0.75"/>
                    <measurement group_id="O5" value="0.750" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.875" lower_limit="0.47" upper_limit="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7824</p_value>
            <method>ANOVA</method>
            <method_desc>Statistical analysis results were obtained using ANOVA with dose level as a fixed effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4056</p_value>
            <method>ANOVA</method>
            <method_desc>Statistical analysis results were obtained using ANOVA with dose level as a fixed effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7599" spread="45.6"/>
                    <measurement group_id="O2" value="3.6691" spread="28.2"/>
                    <measurement group_id="O3" value="29.7502" spread="48.1"/>
                    <measurement group_id="O4" value="63.1772" spread="31.3"/>
                    <measurement group_id="O5" value="98.8228" spread="34.6"/>
                    <measurement group_id="O6" value="272.3381" spread="39.5"/>
                    <measurement group_id="O7" value="372.5881" spread="35.2"/>
                    <measurement group_id="O8" value="1009.0958" spread="32.3"/>
                    <measurement group_id="O9" value="875.0011" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.019</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0606</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0187</ci_lower_limit>
            <ci_upper_limit>1.1026</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6177" spread="50.4"/>
                    <measurement group_id="O2" value="86.4177" spread="18.5"/>
                    <measurement group_id="O3" value="148.6319" spread="64.8"/>
                    <measurement group_id="O4" value="389.8000" spread="43.0"/>
                    <measurement group_id="O5" value="576.1987" spread="31.5"/>
                    <measurement group_id="O6" value="808.3223" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0653" spread="43.9"/>
                    <measurement group_id="O2" value="100.2960" spread="21.2"/>
                    <measurement group_id="O3" value="147.1828" spread="47.8"/>
                    <measurement group_id="O4" value="400.5548" spread="27.6"/>
                    <measurement group_id="O5" value="648.9853" spread="25.3"/>
                    <measurement group_id="O6" value="1011.2702" spread="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.258</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0789</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9628</ci_lower_limit>
            <ci_upper_limit>1.1950</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.144</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0929</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9878</ci_lower_limit>
            <ci_upper_limit>1.1980</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5994" spread="45.6"/>
                    <measurement group_id="O2" value="7.3382" spread="28.2"/>
                    <measurement group_id="O3" value="11.9001" spread="48.1"/>
                    <measurement group_id="O4" value="14.3584" spread="31.3"/>
                    <measurement group_id="O5" value="11.2299" spread="34.6"/>
                    <measurement group_id="O6" value="15.5622" spread="39.5"/>
                    <measurement group_id="O7" value="10.6454" spread="35.2"/>
                    <measurement group_id="O8" value="14.4157" spread="32.3"/>
                    <measurement group_id="O9" value="8.3333" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 24 Hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2314" spread="50.4"/>
                    <measurement group_id="O2" value="15.0292" spread="18.5"/>
                    <measurement group_id="O3" value="11.4332" spread="64.8"/>
                    <measurement group_id="O4" value="15.5920" spread="43.0"/>
                    <measurement group_id="O5" value="12.8044" spread="31.5"/>
                    <measurement group_id="O6" value="13.4720" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4174" spread="43.9"/>
                    <measurement group_id="O2" value="17.4428" spread="21.2"/>
                    <measurement group_id="O3" value="11.3218" spread="47.8"/>
                    <measurement group_id="O4" value="16.0222" spread="27.6"/>
                    <measurement group_id="O5" value="14.4219" spread="25.3"/>
                    <measurement group_id="O6" value="16.8545" spread="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6674" spread="50.3"/>
                    <measurement group_id="O2" value="3.5250" spread="30.3"/>
                    <measurement group_id="O3" value="29.4206" spread="48.1"/>
                    <measurement group_id="O4" value="62.4593" spread="31.9"/>
                    <measurement group_id="O5" value="98.6610" spread="34.4"/>
                    <measurement group_id="O6" value="273.0083" spread="40.0"/>
                    <measurement group_id="O7" value="378.3179" spread="35.5"/>
                    <measurement group_id="O8" value="1024.5599" spread="32.5"/>
                    <measurement group_id="O9" value="903.9858" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0799</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0371</ci_lower_limit>
            <ci_upper_limit>1.1227</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1425" spread="50.2"/>
                    <measurement group_id="O2" value="85.7708" spread="18.3"/>
                    <measurement group_id="O3" value="148.6319" spread="64.8"/>
                    <measurement group_id="O4" value="391.5478" spread="43.2"/>
                    <measurement group_id="O5" value="583.7178" spread="32.2"/>
                    <measurement group_id="O6" value="823.3525" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.201</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0897</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9735</ci_lower_limit>
            <ci_upper_limit>1.2060</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3733" spread="32.1"/>
                    <measurement group_id="O2" value="3.8341" spread="26.8"/>
                    <measurement group_id="O3" value="29.9808" spread="47.4"/>
                    <measurement group_id="O4" value="69.3298" spread="24.2"/>
                    <measurement group_id="O5" value="100.2928" spread="34.3"/>
                    <measurement group_id="O6" value="275.1708" spread="39.6"/>
                    <measurement group_id="O7" value="380.2423" spread="35.2"/>
                    <measurement group_id="O8" value="1030.7508" spread="32.3"/>
                    <measurement group_id="O9" value="907.7704" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.490</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0188</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9734</ci_lower_limit>
            <ci_upper_limit>1.0642</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC∞:Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞:Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8469" spread="49.8"/>
                    <measurement group_id="O2" value="86.7892" spread="18.1"/>
                    <measurement group_id="O3" value="149.9419" spread="64.5"/>
                    <measurement group_id="O4" value="393.8737" spread="43.2"/>
                    <measurement group_id="O5" value="587.4204" spread="31.8"/>
                    <measurement group_id="O6" value="825.6238" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality is declared when the 90% confidence interval of the slope lies entirely within the critical region (0.9679, 1.0321) for the dose range of 0.1 mg to 105 mg.</non_inferiority_desc>
            <p_value>0.224</p_value>
            <method>Power Model</method>
            <param_type>Slope</param_type>
            <param_value>1.0846</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9690</ci_lower_limit>
            <ci_upper_limit>1.2002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rac(AUC): Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 After a Single Dose for TAK-020 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rac(AUC): Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 After a Single Dose for TAK-020 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1285" spread="21.9"/>
                    <measurement group_id="O2" value="1.1606" spread="8.9"/>
                    <measurement group_id="O3" value="0.9903" spread="18.7"/>
                    <measurement group_id="O4" value="1.0628" spread="23.3"/>
                    <measurement group_id="O5" value="1.1263" spread="10.7"/>
                    <measurement group_id="O6" value="1.2511" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rac(Cmax): Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax After a Single Dose for TAK-020 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rac(Cmax): Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax After a Single Dose for TAK-020 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0780" spread="22.9"/>
                    <measurement group_id="O2" value="0.9830" spread="10.5"/>
                    <measurement group_id="O3" value="0.9831" spread="39.4"/>
                    <measurement group_id="O4" value="0.9379" spread="29.2"/>
                    <measurement group_id="O5" value="0.9294" spread="16.3"/>
                    <measurement group_id="O6" value="1.0227" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6312" spread="36.3"/>
                    <measurement group_id="O2" value="3.1058" spread="25.2"/>
                    <measurement group_id="O3" value="5.4190" spread="40.7"/>
                    <measurement group_id="O4" value="5.5003" spread="29.5"/>
                    <measurement group_id="O5" value="4.8674" spread="43.3"/>
                    <measurement group_id="O6" value="6.0440" spread="33.3"/>
                    <measurement group_id="O7" value="4.4473" spread="31.8"/>
                    <measurement group_id="O8" value="6.3742" spread="50.9"/>
                    <measurement group_id="O9" value="3.2901" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3778" spread="46.7"/>
                    <measurement group_id="O2" value="7.0123" spread="14.4"/>
                    <measurement group_id="O3" value="4.9815" spread="73.3"/>
                    <measurement group_id="O4" value="6.4761" spread="47.1"/>
                    <measurement group_id="O5" value="6.6860" spread="33.3"/>
                    <measurement group_id="O6" value="7.0636" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7194" spread="34.2"/>
                    <measurement group_id="O2" value="6.8928" spread="17.7"/>
                    <measurement group_id="O3" value="4.8972" spread="34.5"/>
                    <measurement group_id="O4" value="6.4278" spread="33.0"/>
                    <measurement group_id="O5" value="6.2139" spread="34.1"/>
                    <measurement group_id="O6" value="7.2237" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Disposition Phase Half-life for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Disposition Phase Half-life for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1251" spread="0.16347"/>
                    <measurement group_id="O2" value="1.5323" spread="0.28359"/>
                    <measurement group_id="O3" value="2.2093" spread="0.41162"/>
                    <measurement group_id="O4" value="3.0159" spread="0.70963"/>
                    <measurement group_id="O5" value="4.8384" spread="1.06916"/>
                    <measurement group_id="O6" value="4.2946" spread="1.18227"/>
                    <measurement group_id="O7" value="6.0601" spread="1.55255"/>
                    <measurement group_id="O8" value="6.1098" spread="1.65014"/>
                    <measurement group_id="O9" value="9.0275" spread="4.78526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2z : Terminal Disposition Phase Half-life (T1/2z) for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2z : Terminal Disposition Phase Half-life (T1/2z) for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5948" spread="0.42162"/>
                    <measurement group_id="O2" value="3.3397" spread="0.96341"/>
                    <measurement group_id="O3" value="4.1895" spread="0.40518"/>
                    <measurement group_id="O4" value="4.8507" spread="2.21078"/>
                    <measurement group_id="O5" value="6.0124" spread="2.30297"/>
                    <measurement group_id="O6" value="6.2971" spread="1.82711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1537" spread="0.42833"/>
                    <measurement group_id="O2" value="3.2089" spread="0.77467"/>
                    <measurement group_id="O3" value="4.1335" spread="0.51741"/>
                    <measurement group_id="O4" value="3.7934" spread="0.70657"/>
                    <measurement group_id="O5" value="5.1273" spread="1.58301"/>
                    <measurement group_id="O6" value="5.4635" spread="1.47268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lambda z (Λz): Terminal Disposition Phase Rate Constant for TAK-020 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda z (Λz): Terminal Disposition Phase Rate Constant for TAK-020 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6226" spread="0.09046"/>
                    <measurement group_id="O2" value="0.4659" spread="0.08893"/>
                    <measurement group_id="O3" value="0.3223" spread="0.05573"/>
                    <measurement group_id="O4" value="0.2402" spread="0.05603"/>
                    <measurement group_id="O5" value="0.1496" spread="0.03468"/>
                    <measurement group_id="O6" value="0.1745" spread="0.05957"/>
                    <measurement group_id="O7" value="0.1202" spread="0.02831"/>
                    <measurement group_id="O8" value="0.1216" spread="0.03677"/>
                    <measurement group_id="O9" value="0.1004" spread="0.06068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Statistical analysis results were obtained using ANOVA with dose level as a fixed effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lamda z (Λz):Terminal Disposition Phase Rate Constant for TAK-020 (MRD)</title>
        <time_frame>From pre-dose to 96 hours post-dose in Part 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Lamda z (Λz):Terminal Disposition Phase Rate Constant for TAK-020 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2732" spread="0.04550"/>
                    <measurement group_id="O2" value="0.2231" spread="0.06562"/>
                    <measurement group_id="O3" value="0.1667" spread="0.01608"/>
                    <measurement group_id="O4" value="0.1655" spread="0.05994"/>
                    <measurement group_id="O5" value="0.1263" spread="0.03599"/>
                    <measurement group_id="O6" value="0.1216" spread="0.04880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3325" spread="0.07185"/>
                    <measurement group_id="O2" value="0.2264" spread="0.05325"/>
                    <measurement group_id="O3" value="0.1699" spread="0.02117"/>
                    <measurement group_id="O4" value="0.1880" spread="0.03581"/>
                    <measurement group_id="O5" value="0.1471" spread="0.04752"/>
                    <measurement group_id="O6" value="0.1363" spread="0.04310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.000" upper_limit="0.250"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.000" upper_limit="0.220"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O4" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O5" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O6" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O7" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O8" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O9" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O4" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O5" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O6" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O4" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O5" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O6" value="0.0000" lower_limit="0.000" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 1 (SRD)</title>
        <description>CL/F was calculated as dose/AUC∞.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 1 (SRD)</title>
          <description>CL/F was calculated as dose/AUC∞.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6058" spread="22.96089"/>
                    <measurement group_id="O2" value="134.3327" spread="36.96594"/>
                    <measurement group_id="O3" value="90.8722" spread="42.30328"/>
                    <measurement group_id="O4" value="64.9449" spread="15.91608"/>
                    <measurement group_id="O5" value="92.1842" spread="34.02451"/>
                    <measurement group_id="O6" value="67.4975" spread="25.25161"/>
                    <measurement group_id="O7" value="96.6058" spread="32.53095"/>
                    <measurement group_id="O8" value="70.7695" spread="22.35098"/>
                    <measurement group_id="O9" value="116.6389" spread="16.07341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 2 (MRD)</title>
        <description>CL/F was calculated as dose/AUCτ.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 2 (MRD)</title>
          <description>CL/F was calculated as dose/AUCτ.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3171" spread="58.62331"/>
                    <measurement group_id="O2" value="67.1355" spread="11.81065"/>
                    <measurement group_id="O3" value="100.6915" spread="62.33954"/>
                    <measurement group_id="O4" value="68.2909" spread="29.74598"/>
                    <measurement group_id="O5" value="79.5377" spread="22.34558"/>
                    <measurement group_id="O6" value="76.9650" spread="28.27771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.2882" spread="42.85829"/>
                    <measurement group_id="O2" value="58.3884" spread="12.20159"/>
                    <measurement group_id="O3" value="96.5521" spread="46.88638"/>
                    <measurement group_id="O4" value="64.1696" spread="16.00068"/>
                    <measurement group_id="O5" value="71.1027" spread="16.99648"/>
                    <measurement group_id="O6" value="64.2873" spread="29.63651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)</title>
        <description>Vz/F was calculated as (CL/F)/λz.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)</title>
          <description>Vz/F was calculated as (CL/F)/λz.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3923" spread="19.67518"/>
                    <measurement group_id="O2" value="292.2714" spread="78.43782"/>
                    <measurement group_id="O3" value="290.5190" spread="160.50093"/>
                    <measurement group_id="O4" value="281.7423" spread="101.64610"/>
                    <measurement group_id="O5" value="655.4794" spread="320.11459"/>
                    <measurement group_id="O6" value="416.8746" spread="183.79449"/>
                    <measurement group_id="O7" value="807.4773" spread="200.14983"/>
                    <measurement group_id="O8" value="594.3399" spread="149.97225"/>
                    <measurement group_id="O9" value="1573.1600" spread="901.24407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)</title>
        <description>Vz/F was calculated as (CL/F)/λz.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)</title>
          <description>Vz/F was calculated as (CL/F)/λz.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442.5900" spread="248.99792"/>
                    <measurement group_id="O2" value="329.6057" spread="135.47030"/>
                    <measurement group_id="O3" value="632.4288" spread="438.98268"/>
                    <measurement group_id="O4" value="460.7824" spread="218.14865"/>
                    <measurement group_id="O5" value="698.3679" spread="373.79793"/>
                    <measurement group_id="O6" value="715.0788" spread="414.96986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.8037" spread="178.07012"/>
                    <measurement group_id="O2" value="266.5672" spread="68.21454"/>
                    <measurement group_id="O3" value="565.3577" spread="252.08686"/>
                    <measurement group_id="O4" value="352.4564" spread="114.45822"/>
                    <measurement group_id="O5" value="530.4696" spread="211.00235"/>
                    <measurement group_id="O6" value="503.3324" spread="298.76176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae(0-24) : Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 1 (SRD)</title>
        <description>Ae(0-24) was calculated as calculated as Cur*Vur, where Cur was the concentration of drug excreted in urine and Vur is the volume of urine excreted.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae(0-24) : Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 1 (SRD)</title>
          <description>Ae(0-24) was calculated as calculated as Cur*Vur, where Cur was the concentration of drug excreted in urine and Vur is the volume of urine excreted.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002473" spread="0.0008033"/>
                    <measurement group_id="O2" value="0.009898" spread="0.0049671"/>
                    <measurement group_id="O3" value="0.069183" spread="0.0289653"/>
                    <measurement group_id="O4" value="0.128195" spread="0.0412071"/>
                    <measurement group_id="O5" value="0.227985" spread="0.0762743"/>
                    <measurement group_id="O6" value="0.507260" spread="0.1109721"/>
                    <measurement group_id="O7" value="0.963253" spread="0.3108451"/>
                    <measurement group_id="O8" value="2.010763" spread="0.3615714"/>
                    <measurement group_id="O9" value="1.925176" spread="0.6269670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae(0-24): Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 2 (MRD)</title>
        <description>Ae(0-24) is calculated as calculated as Cur*Vur, where Cu was the concentration of drug excreted in urine and Vur is the volume of urine excreted.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 1 and Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae(0-24): Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 2 (MRD)</title>
          <description>Ae(0-24) is calculated as calculated as Cur*Vur, where Cu was the concentration of drug excreted in urine and Vur is the volume of urine excreted.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086153" spread="0.0362135"/>
                    <measurement group_id="O2" value="0.149595" spread="0.0378613"/>
                    <measurement group_id="O3" value="0.418761" spread="0.1666534"/>
                    <measurement group_id="O4" value="1.095832" spread="0.4029873"/>
                    <measurement group_id="O5" value="1.186754" spread="0.3087747"/>
                    <measurement group_id="O6" value="1.569498" spread="0.3542760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.089955" spread="0.0423540"/>
                    <measurement group_id="O2" value="0.181305" spread="0.0555997"/>
                    <measurement group_id="O3" value="0.385163" spread="0.1034764"/>
                    <measurement group_id="O4" value="1.004047" spread="0.2138181"/>
                    <measurement group_id="O5" value="1.370011" spread="0.3414174"/>
                    <measurement group_id="O6" value="2.165337" spread="0.3525765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae(0-96): Amount of Drug Excreted in Urine From Time 0 to Time 96 Hours for TAK-020 in Part 1 (SRD)</title>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae(0-96): Amount of Drug Excreted in Urine From Time 0 to Time 96 Hours for TAK-020 in Part 1 (SRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002473" spread="0.0008033"/>
                    <measurement group_id="O2" value="0.009999" spread="0.0049464"/>
                    <measurement group_id="O3" value="0.069676" spread="0.0288376"/>
                    <measurement group_id="O4" value="0.128604" spread="0.0411008"/>
                    <measurement group_id="O5" value="0.229946" spread="0.0763608"/>
                    <measurement group_id="O6" value="0.514036" spread="0.1144776"/>
                    <measurement group_id="O7" value="0.977421" spread="0.3148372"/>
                    <measurement group_id="O8" value="2.062580" spread="0.3829068"/>
                    <measurement group_id="O9" value="1.988120" spread="0.6152605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)</title>
        <description>Fe was calculated as (Aet/dose)*100.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)</title>
          <description>Fe was calculated as (Aet/dose)*100.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>percentage of TAK-020 dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4733" spread="0.80334"/>
                    <measurement group_id="O2" value="1.9796" spread="0.99341"/>
                    <measurement group_id="O3" value="2.7673" spread="1.15861"/>
                    <measurement group_id="O4" value="2.9135" spread="0.93653"/>
                    <measurement group_id="O5" value="2.5907" spread="0.86675"/>
                    <measurement group_id="O6" value="2.8986" spread="0.63413"/>
                    <measurement group_id="O7" value="2.7522" spread="0.88813"/>
                    <measurement group_id="O8" value="2.8725" spread="0.51653"/>
                    <measurement group_id="O9" value="1.8335" spread="0.59711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 2 (MRD)</title>
        <description>Fe was calculated as (Aet/dose)*100.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 1 and Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 2 (MRD)</title>
          <description>Fe was calculated as (Aet/dose)*100.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>percentage of TAK-020 dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2974" spread="0.96569"/>
                    <measurement group_id="O2" value="2.6016" spread="0.65846"/>
                    <measurement group_id="O3" value="3.2212" spread="1.28195"/>
                    <measurement group_id="O4" value="4.3833" spread="1.61195"/>
                    <measurement group_id="O5" value="2.6372" spread="0.68617"/>
                    <measurement group_id="O6" value="2.6158" spread="0.59046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3988" spread="1.12944"/>
                    <measurement group_id="O2" value="3.1531" spread="0.96695"/>
                    <measurement group_id="O3" value="2.9628" spread="0.79597"/>
                    <measurement group_id="O4" value="4.0162" spread="0.85527"/>
                    <measurement group_id="O5" value="3.0445" spread="0.75871"/>
                    <measurement group_id="O6" value="3.6089" spread="0.58763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fe(0-96): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)</title>
        <description>Fe was calculated as (Aet/dose)*100.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe(0-96): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)</title>
          <description>Fe was calculated as (Aet/dose)*100.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>percentage of TAK-020 dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4733" spread="0.80334"/>
                    <measurement group_id="O2" value="1.9999" spread="0.98928"/>
                    <measurement group_id="O3" value="2.7870" spread="1.15351"/>
                    <measurement group_id="O4" value="2.9228" spread="0.93411"/>
                    <measurement group_id="O5" value="2.6130" spread="0.86774"/>
                    <measurement group_id="O6" value="2.9373" spread="0.65416"/>
                    <measurement group_id="O7" value="2.7926" spread="0.89953"/>
                    <measurement group_id="O8" value="2.9465" spread="0.54701"/>
                    <measurement group_id="O9" value="1.8934" spread="0.58596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr) for TAK-020 in Part 1 (SRD)</title>
        <description>CLr was calculated as (Ae96/AUCt)*100.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 96 hours) post-dose in Part 1</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
            <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
            <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
            <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
            <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
            <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
            <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 Cohort 7: TAK-020 35 mg</title>
            <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
          </group>
          <group group_id="O8">
            <title>Part 1 Cohort 8: TAK-020 70 mg</title>
            <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
          </group>
          <group group_id="O9">
            <title>Part 1 Cohort 9: TAK-020 105 mg</title>
            <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) for TAK-020 in Part 1 (SRD)</title>
          <description>CLr was calculated as (Ae96/AUCt)*100.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6856" spread="1.20477"/>
                    <measurement group_id="O2" value="2.6010" spread="0.62075"/>
                    <measurement group_id="O3" value="2.5250" spread="1.30987"/>
                    <measurement group_id="O4" value="2.0190" spread="0.47688"/>
                    <measurement group_id="O5" value="2.2159" spread="0.15331"/>
                    <measurement group_id="O6" value="1.8896" spread="0.60426"/>
                    <measurement group_id="O7" value="2.6108" spread="1.03807"/>
                    <measurement group_id="O8" value="2.0007" spread="0.28823"/>
                    <measurement group_id="O9" value="2.1898" spread="0.63728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr) for TAK-020 in Part 2 (MRD)</title>
        <description>CLr was calculated as (Ae24/AUC24)*100.</description>
        <time_frame>Pre-dose and multiple timepoints (up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) for TAK-020 in Part 2 (MRD)</title>
          <description>CLr was calculated as (Ae24/AUC24)*100.</description>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine. Here, number analyzed are the participants who were evaluated for this outcome measure.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3165" spread="0.35669"/>
                    <measurement group_id="O2" value="1.7168" spread="0.42806"/>
                    <measurement group_id="O3" value="2.8969" spread="1.50559"/>
                    <measurement group_id="O4" value="2.6497" spread="0.42235"/>
                    <measurement group_id="O5" value="2.1525" spread="0.83694"/>
                    <measurement group_id="O6" value="1.9597" spread="0.52835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0802" spread="0.36760"/>
                    <measurement group_id="O2" value="1.7732" spread="0.41318"/>
                    <measurement group_id="O3" value="2.6754" spread="1.08869"/>
                    <measurement group_id="O4" value="2.5311" spread="0.65737"/>
                    <measurement group_id="O5" value="2.2053" spread="0.80067"/>
                    <measurement group_id="O6" value="2.2405" spread="0.82268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>R: Linearity Index Calculated as AUC24 at Steady State/AUC∞ After a Single Dose for TAK-020 in Part 2 (MRD)</title>
        <time_frame>Pre-dose and multiple timepoints (Up to 48 hours) post-dose on Day 1 and pre-dose and multiple timepoints (up to 24 hours) post-dose on Day 9 in Part 2</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
            <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
            <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 Cohort 3: TAK-020 13 mg</title>
            <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2 Cohort 4: TAK-020 25 mg</title>
            <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2 Cohort 5: TAK-020 45 mg</title>
            <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 2 Cohort 6: TAK-020 60 mg</title>
            <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>R: Linearity Index Calculated as AUC24 at Steady State/AUC∞ After a Single Dose for TAK-020 in Part 2 (MRD)</title>
          <population>Pharmacokinetic set included all participants who received study drug and had at least one measurable plasma concentration or amount of drug in the urine.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.551" spread="0.1578"/>
                    <measurement group_id="O2" value="4.463" spread="0.1578"/>
                    <measurement group_id="O3" value="5.010" spread="0.1578"/>
                    <measurement group_id="O4" value="5.940" spread="0.1728"/>
                    <measurement group_id="O5" value="6.376" spread="0.1578"/>
                    <measurement group_id="O6" value="6.716" spread="0.1578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.665" spread="0.1578"/>
                    <measurement group_id="O2" value="4.608" spread="0.1578"/>
                    <measurement group_id="O3" value="4.992" spread="0.1578"/>
                    <measurement group_id="O4" value="5.993" spread="0.1728"/>
                    <measurement group_id="O5" value="6.475" spread="0.1578"/>
                    <measurement group_id="O6" value="6.919" spread="0.1578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Ratio</param_type>
            <param_value>1.121</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.772</ci_lower_limit>
            <ci_upper_limit>1.628</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Ratio</param_type>
            <param_value>1.156</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.796</ci_lower_limit>
            <ci_upper_limit>1.678</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Ratio</param_type>
            <param_value>0.982</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.676</ci_lower_limit>
            <ci_upper_limit>1.425</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Ratio</param_type>
            <param_value>1.055</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.701</ci_lower_limit>
            <ci_upper_limit>1.587</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Ratio</param_type>
            <param_value>1.105</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.761</ci_lower_limit>
            <ci_upper_limit>1.604</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Estimated Ratio</param_type>
            <param_value>1.225</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.844</ci_lower_limit>
            <ci_upper_limit>1.778</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug up to and including 30 days after last dose of study drug ( 31 Days for Part 1 and 39 days for Part 2)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 Cohort 1-9: Placebo</title>
          <description>TAK-020 placebo-matching solution, orally, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 Cohort 1: TAK-020 0.1 mg</title>
          <description>TAK-020 0.1 milligram (mg), solution, orally once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Cohort 2: TAK-020 0.5 mg</title>
          <description>TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1 Cohort 3: TAK-020 2.5 mg</title>
          <description>TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.</description>
        </group>
        <group group_id="E5">
          <title>Part 1 Cohort 4: TAK-020 4.4 mg</title>
          <description>TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.</description>
        </group>
        <group group_id="E6">
          <title>Part 1 Cohort 5: TAK-020 8.8 mg</title>
          <description>TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.</description>
        </group>
        <group group_id="E7">
          <title>Part 1 Cohort 6: TAK-020 17.5 mg</title>
          <description>TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.</description>
        </group>
        <group group_id="E8">
          <title>Part 1 Cohort 7: TAK-020 35 mg</title>
          <description>TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 6.</description>
        </group>
        <group group_id="E9">
          <title>Part 1 Cohort 8: TAK-020 70 mg</title>
          <description>TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 7.</description>
        </group>
        <group group_id="E10">
          <title>Part 1 Cohort 9: TAK-020 105 mg</title>
          <description>TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose was determined based on review of safety, tolerability and PK data from Cohort 8.</description>
        </group>
        <group group_id="E11">
          <title>Part 2 Cohort 1-6: Placebo</title>
          <description>TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.</description>
        </group>
        <group group_id="E12">
          <title>Part 2 Cohort 1: TAK-020 3.75 mg</title>
          <description>TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.</description>
        </group>
        <group group_id="E13">
          <title>Part 2 Cohort 2: TAK-020 5.75 mg</title>
          <description>TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.</description>
        </group>
        <group group_id="E14">
          <title>Part 2 Cohort 3: TAK-020 13 mg</title>
          <description>TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.</description>
        </group>
        <group group_id="E15">
          <title>Part 2 Cohort 4: TAK-020 25 mg</title>
          <description>TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.</description>
        </group>
        <group group_id="E16">
          <title>Part 2 Cohort 5: TAK-020 45 mg</title>
          <description>TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.</description>
        </group>
        <group group_id="E17">
          <title>Part 2 Cohort 6: TAK-020 60 mg</title>
          <description>TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version: 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

